[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIq0qTsYIHm28yWXs7PuB9udvjJd62EyY8M5E8ihxn2E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"UMC Utrecht",[4],359,false,71,35,1380782,55,275,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Breast Cancer",14,{"name":18,"count":19},"Coronary Artery Disease",11,{"name":21,"count":22},"Hypertension",10,{"name":24,"count":25},"Delirium",7,{"name":27,"count":28},"Prostate Cancer",6,{"name":30,"count":28},"Cardiovascular Diseases",{"name":32,"count":28},"Heart Failure",{"name":34,"count":35},"Infertility",5,[37,42,47,52,57,62,67,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05080569","Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment","2025-12","Progesterone Vaginal Product",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02735707","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","2026-02","Ceftriaxone",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03211793","Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","2026-11-01","Mesenchymal stromal cells",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06285539","Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases","2026-12","Filgotinib",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05939037","Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy","2026-12-31","Zanubrutinib Oral Product",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05832580","The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum","2027-03-29","Etidronate",{"nctId":68,"briefTitle":69,"date":70,"intervention":66},"NCT05662111","Treatment of Ectopic Calcification in Fahr's Disease or Syndrome","2027-12",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06563986","FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer","2028-01","Systemic treatment",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT07276425","Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis","2028-06-01","Dupilumab",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06524570","Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy","2030-08-01","ICI",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,122,154,233,267,294,312,330,348,366,384,402,420,438,456,474,492,510,528,546,564,582,600,618,636,654,672,690,708,726,744,762,780,798,816,834,852,870,888,906,924,942,960,978,996,1014,1032,1050,1068,1090,1117,1139,1160,1183,1205,1225,1266,1302,1327,1352,1378,1396,1425,1443,1461,1485,1510,1538,1564,1582,1600,1628,1646,1664,1682,1705,1730,1753,1778,1804,1826,1853,1871,1896,1922,1940,1967,1993,2018,2044,2069,2095,2120,2146,2170,2194,2219,2248,2266,2284,2312,2330,2353,2377,2406,2432,2457,2482,2500,2518,2536,2554,2579,2605,2631,2649,2680,2707,2734,2759,2783,2808,2836,2860,2887,2916,2934,2967,2992,3017,3040,3064,3090,3118,3141,3168,3191,3216,3240,3267,3285,3309,3334,3352],{"intervention":41,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":120},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":40},[108],{"nctId":38,"briefTitle":39,"status":109,"phases":110,"primaryCompletion":40,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":119},"RECRUITING",[91],"2027-07","2023-03-01",1008,[115,116,117,118],"Pregnancy Related","Fertility Issues","Luteal Phase Defect","Infertility Unexplained",[41],{"trials":121,"activeCount":99},[],{"intervention":66,"totalTrials":123,"cells":124},2,{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":140,"PHASE4":150,"NA":152},{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":95,"soonestReadout":70},[131],{"nctId":68,"briefTitle":69,"status":109,"phases":132,"primaryCompletion":70,"completion":70,"start":133,"enrollment":134,"conditions":135,"interventions":139},[89],"2023-04-03",98,[136,137,138],"Fahr Disease","Fahr Syndrome","Primary Familial Brain Calcification",[66],{"trials":141,"activeCount":95,"soonestReadout":65},[142],{"nctId":63,"briefTitle":64,"status":109,"phases":143,"primaryCompletion":65,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},[90],"2027-04-29","2023-04-26",76,[148],"Pseudoxanthoma Elasticum",[66],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":99},[],{"intervention":155,"totalTrials":123,"cells":156},"Hydroxychloroquine",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":217,"NA":231},{"trials":158,"activeCount":99},[],{"trials":160,"activeCount":99},[],{"trials":162,"activeCount":99},[],{"trials":164,"activeCount":95,"soonestReadout":45},[165],{"nctId":43,"briefTitle":44,"status":109,"phases":166,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},[90],"2028-02","2016-04-11",20000,[171],"Community-acquired Pneumonia, Influenza, COVID-19",[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],"Moxifloxacin or Levofloxacin","Piperacillin-tazobactam","Ceftaroline","Amoxicillin-clavulanate","Standard course macrolide","Extended course macrolide","Fixed-duration Hydrocortisone","Shock-dependent hydrocortisone","Fixed-duration higher dose Hydrocortisone","Five-days oseltamivir","Ten-days oseltamivir","Lopinavir \u002F Ritonavir","Hydroxychloroquine + lopinavir\u002Fritonavir","Ivermectin","Interferon beta-1a","Anakinra","Tocilizumab","Sarilumab","Local standard venous thromboprophylaxis","Therapeutic dose anticoagulation","Conventional low dose thromboprophylaxis","Intermediate dose thromboprophylaxis","Continuation of therapeutic dose anticoagulation","Convalescent plasma","Delayed administration of convalescent plasma","Vitamin C","Aspirin","P2Y12 inhibitor","Simvastatin","Eritoran","Apremilast","Angiotensin converting enzyme inhibitor","Angiotensin Receptor Blockers","ARB + DMX-200","Cysteamine","Fixed-duration dexamethasone","Baloxavir Marboxil","Five-days oseltamivir + baloxavir marboxil","Ten-days oseltamivir + baloxavir marboxil","Imatinib","Baricitinib","Nirmatrelvir\u002Fritonavir","Remdesivir","Nirmatrelvir\u002Fritonavir + remdesivir",{"trials":218,"activeCount":99},[219],{"nctId":220,"briefTitle":221,"status":222,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT04362332","Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","TERMINATED",[91],"2020-06-08","2020-04-14",25,[228],"COVID-19",[230,155],"Chloroquine Sulfate",{"trials":232,"activeCount":99},[],{"intervention":199,"totalTrials":123,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":257,"PHASE4":263,"NA":265},{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[241],{"nctId":242,"briefTitle":243,"status":244,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":252},"NCT02565693","Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation","COMPLETED",[89],"2021-01-31","2014-09",101,[250,251],"Cerebral Hemorrhage","Atrial Fibrillation",[253,199,254,255,256],"Apixaban","Carbasalate calcium","Clopidogrel","Dipyridamole",{"trials":258,"activeCount":95,"soonestReadout":45},[259],{"nctId":43,"briefTitle":44,"status":109,"phases":260,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":261,"interventions":262},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":264,"activeCount":99},[],{"trials":266,"activeCount":99},[],{"intervention":212,"totalTrials":123,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":284,"PHASE4":290,"NA":292},{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":99},[],{"trials":274,"activeCount":99},[275],{"nctId":276,"briefTitle":277,"status":222,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":35,"conditions":281,"interventions":283},"NCT02685046","Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy",[89],"2019-09-01","2016-04",[282],"Colonic Neoplasms",[212],{"trials":285,"activeCount":95,"soonestReadout":45},[286],{"nctId":43,"briefTitle":44,"status":109,"phases":287,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":288,"interventions":289},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":291,"activeCount":99},[],{"trials":293,"activeCount":99},[],{"intervention":46,"totalTrials":95,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":308,"NA":310},{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":99},[],{"trials":301,"activeCount":99},[],{"trials":303,"activeCount":95,"soonestReadout":45},[304],{"nctId":43,"briefTitle":44,"status":109,"phases":305,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":306,"interventions":307},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":309,"activeCount":99},[],{"trials":311,"activeCount":99},[],{"intervention":173,"totalTrials":95,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":326,"NA":328},{"trials":315,"activeCount":99},[],{"trials":317,"activeCount":99},[],{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":95,"soonestReadout":45},[322],{"nctId":43,"briefTitle":44,"status":109,"phases":323,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":324,"interventions":325},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":327,"activeCount":99},[],{"trials":329,"activeCount":99},[],{"intervention":174,"totalTrials":95,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":344,"NA":346},{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":99},[],{"trials":337,"activeCount":99},[],{"trials":339,"activeCount":95,"soonestReadout":45},[340],{"nctId":43,"briefTitle":44,"status":109,"phases":341,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":342,"interventions":343},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":99},[],{"intervention":175,"totalTrials":95,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":362,"NA":364},{"trials":351,"activeCount":99},[],{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":95,"soonestReadout":45},[358],{"nctId":43,"briefTitle":44,"status":109,"phases":359,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":360,"interventions":361},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":99},[],{"intervention":176,"totalTrials":95,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":380,"NA":382},{"trials":369,"activeCount":99},[],{"trials":371,"activeCount":99},[],{"trials":373,"activeCount":99},[],{"trials":375,"activeCount":95,"soonestReadout":45},[376],{"nctId":43,"briefTitle":44,"status":109,"phases":377,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":378,"interventions":379},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":99},[],{"intervention":177,"totalTrials":95,"cells":385},{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":398,"NA":400},{"trials":387,"activeCount":99},[],{"trials":389,"activeCount":99},[],{"trials":391,"activeCount":99},[],{"trials":393,"activeCount":95,"soonestReadout":45},[394],{"nctId":43,"briefTitle":44,"status":109,"phases":395,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":396,"interventions":397},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":399,"activeCount":99},[],{"trials":401,"activeCount":99},[],{"intervention":178,"totalTrials":95,"cells":403},{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":416,"NA":418},{"trials":405,"activeCount":99},[],{"trials":407,"activeCount":99},[],{"trials":409,"activeCount":99},[],{"trials":411,"activeCount":95,"soonestReadout":45},[412],{"nctId":43,"briefTitle":44,"status":109,"phases":413,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":414,"interventions":415},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":417,"activeCount":99},[],{"trials":419,"activeCount":99},[],{"intervention":179,"totalTrials":95,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":434,"NA":436},{"trials":423,"activeCount":99},[],{"trials":425,"activeCount":99},[],{"trials":427,"activeCount":99},[],{"trials":429,"activeCount":95,"soonestReadout":45},[430],{"nctId":43,"briefTitle":44,"status":109,"phases":431,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":432,"interventions":433},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"intervention":180,"totalTrials":95,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":452,"NA":454},{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"trials":445,"activeCount":99},[],{"trials":447,"activeCount":95,"soonestReadout":45},[448],{"nctId":43,"briefTitle":44,"status":109,"phases":449,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":450,"interventions":451},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"intervention":181,"totalTrials":95,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":470,"NA":472},{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":95,"soonestReadout":45},[466],{"nctId":43,"briefTitle":44,"status":109,"phases":467,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":468,"interventions":469},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":99},[],{"intervention":182,"totalTrials":95,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":488,"NA":490},{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":95,"soonestReadout":45},[484],{"nctId":43,"briefTitle":44,"status":109,"phases":485,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":486,"interventions":487},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[],{"intervention":183,"totalTrials":95,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":506,"NA":508},{"trials":495,"activeCount":99},[],{"trials":497,"activeCount":99},[],{"trials":499,"activeCount":99},[],{"trials":501,"activeCount":95,"soonestReadout":45},[502],{"nctId":43,"briefTitle":44,"status":109,"phases":503,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":504,"interventions":505},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"intervention":184,"totalTrials":95,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":524,"NA":526},{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":95,"soonestReadout":45},[520],{"nctId":43,"briefTitle":44,"status":109,"phases":521,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":522,"interventions":523},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"intervention":185,"totalTrials":95,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":99},[],{"trials":533,"activeCount":99},[],{"trials":535,"activeCount":99},[],{"trials":537,"activeCount":95,"soonestReadout":45},[538],{"nctId":43,"briefTitle":44,"status":109,"phases":539,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":540,"interventions":541},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":99},[],{"intervention":186,"totalTrials":95,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":560,"NA":562},{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":95,"soonestReadout":45},[556],{"nctId":43,"briefTitle":44,"status":109,"phases":557,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":558,"interventions":559},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":99},[],{"intervention":187,"totalTrials":95,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":578,"NA":580},{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":99},[],{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":95,"soonestReadout":45},[574],{"nctId":43,"briefTitle":44,"status":109,"phases":575,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":576,"interventions":577},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":579,"activeCount":99},[],{"trials":581,"activeCount":99},[],{"intervention":188,"totalTrials":95,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":596,"NA":598},{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[],{"trials":589,"activeCount":99},[],{"trials":591,"activeCount":95,"soonestReadout":45},[592],{"nctId":43,"briefTitle":44,"status":109,"phases":593,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":594,"interventions":595},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"intervention":189,"totalTrials":95,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":614,"NA":616},{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"trials":607,"activeCount":99},[],{"trials":609,"activeCount":95,"soonestReadout":45},[610],{"nctId":43,"briefTitle":44,"status":109,"phases":611,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":612,"interventions":613},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":615,"activeCount":99},[],{"trials":617,"activeCount":99},[],{"intervention":190,"totalTrials":95,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":632,"NA":634},{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":95,"soonestReadout":45},[628],{"nctId":43,"briefTitle":44,"status":109,"phases":629,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":630,"interventions":631},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":99},[],{"intervention":191,"totalTrials":95,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":650,"NA":652},{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":95,"soonestReadout":45},[646],{"nctId":43,"briefTitle":44,"status":109,"phases":647,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":648,"interventions":649},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":651,"activeCount":99},[],{"trials":653,"activeCount":99},[],{"intervention":192,"totalTrials":95,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":668,"NA":670},{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":95,"soonestReadout":45},[664],{"nctId":43,"briefTitle":44,"status":109,"phases":665,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":666,"interventions":667},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":99},[],{"intervention":193,"totalTrials":95,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":686,"NA":688},{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":95,"soonestReadout":45},[682],{"nctId":43,"briefTitle":44,"status":109,"phases":683,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":684,"interventions":685},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":687,"activeCount":99},[],{"trials":689,"activeCount":99},[],{"intervention":194,"totalTrials":95,"cells":691},{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":704,"NA":706},{"trials":693,"activeCount":99},[],{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":95,"soonestReadout":45},[700],{"nctId":43,"briefTitle":44,"status":109,"phases":701,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":702,"interventions":703},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[],{"intervention":195,"totalTrials":95,"cells":709},{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":716,"PHASE4":722,"NA":724},{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"trials":715,"activeCount":99},[],{"trials":717,"activeCount":95,"soonestReadout":45},[718],{"nctId":43,"briefTitle":44,"status":109,"phases":719,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":720,"interventions":721},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":723,"activeCount":99},[],{"trials":725,"activeCount":99},[],{"intervention":196,"totalTrials":95,"cells":727},{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":740,"NA":742},{"trials":729,"activeCount":99},[],{"trials":731,"activeCount":99},[],{"trials":733,"activeCount":99},[],{"trials":735,"activeCount":95,"soonestReadout":45},[736],{"nctId":43,"briefTitle":44,"status":109,"phases":737,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":738,"interventions":739},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":741,"activeCount":99},[],{"trials":743,"activeCount":99},[],{"intervention":197,"totalTrials":95,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":758,"NA":760},{"trials":747,"activeCount":99},[],{"trials":749,"activeCount":99},[],{"trials":751,"activeCount":99},[],{"trials":753,"activeCount":95,"soonestReadout":45},[754],{"nctId":43,"briefTitle":44,"status":109,"phases":755,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":756,"interventions":757},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":99},[],{"intervention":198,"totalTrials":95,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":776,"NA":778},{"trials":765,"activeCount":99},[],{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":99},[],{"trials":771,"activeCount":95,"soonestReadout":45},[772],{"nctId":43,"briefTitle":44,"status":109,"phases":773,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":774,"interventions":775},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":99},[],{"intervention":200,"totalTrials":95,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":794,"NA":796},{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":99},[],{"trials":787,"activeCount":99},[],{"trials":789,"activeCount":95,"soonestReadout":45},[790],{"nctId":43,"briefTitle":44,"status":109,"phases":791,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":792,"interventions":793},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[],{"intervention":201,"totalTrials":95,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":812,"NA":814},{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":99},[],{"trials":807,"activeCount":95,"soonestReadout":45},[808],{"nctId":43,"briefTitle":44,"status":109,"phases":809,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":810,"interventions":811},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":813,"activeCount":99},[],{"trials":815,"activeCount":99},[],{"intervention":202,"totalTrials":95,"cells":817},{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":830,"NA":832},{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":99},[],{"trials":823,"activeCount":99},[],{"trials":825,"activeCount":95,"soonestReadout":45},[826],{"nctId":43,"briefTitle":44,"status":109,"phases":827,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":828,"interventions":829},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":831,"activeCount":99},[],{"trials":833,"activeCount":99},[],{"intervention":203,"totalTrials":95,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":848,"NA":850},{"trials":837,"activeCount":99},[],{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":95,"soonestReadout":45},[844],{"nctId":43,"briefTitle":44,"status":109,"phases":845,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":846,"interventions":847},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":849,"activeCount":99},[],{"trials":851,"activeCount":99},[],{"intervention":204,"totalTrials":95,"cells":853},{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":866,"NA":868},{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":99},[],{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":95,"soonestReadout":45},[862],{"nctId":43,"briefTitle":44,"status":109,"phases":863,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":864,"interventions":865},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"intervention":205,"totalTrials":95,"cells":871},{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":884,"NA":886},{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":95,"soonestReadout":45},[880],{"nctId":43,"briefTitle":44,"status":109,"phases":881,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":882,"interventions":883},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":99},[],{"intervention":206,"totalTrials":95,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":902,"NA":904},{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":95,"soonestReadout":45},[898],{"nctId":43,"briefTitle":44,"status":109,"phases":899,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":900,"interventions":901},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":99},[],{"intervention":207,"totalTrials":95,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":920,"NA":922},{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":95,"soonestReadout":45},[916],{"nctId":43,"briefTitle":44,"status":109,"phases":917,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":918,"interventions":919},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":921,"activeCount":99},[],{"trials":923,"activeCount":99},[],{"intervention":208,"totalTrials":95,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":938,"NA":940},{"trials":927,"activeCount":99},[],{"trials":929,"activeCount":99},[],{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":95,"soonestReadout":45},[934],{"nctId":43,"briefTitle":44,"status":109,"phases":935,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":936,"interventions":937},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":939,"activeCount":99},[],{"trials":941,"activeCount":99},[],{"intervention":209,"totalTrials":95,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":956,"NA":958},{"trials":945,"activeCount":99},[],{"trials":947,"activeCount":99},[],{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":95,"soonestReadout":45},[952],{"nctId":43,"briefTitle":44,"status":109,"phases":953,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":954,"interventions":955},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"intervention":210,"totalTrials":95,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":974,"NA":976},{"trials":963,"activeCount":99},[],{"trials":965,"activeCount":99},[],{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":95,"soonestReadout":45},[970],{"nctId":43,"briefTitle":44,"status":109,"phases":971,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":972,"interventions":973},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":975,"activeCount":99},[],{"trials":977,"activeCount":99},[],{"intervention":211,"totalTrials":95,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":992,"NA":994},{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":95,"soonestReadout":45},[988],{"nctId":43,"briefTitle":44,"status":109,"phases":989,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":990,"interventions":991},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":993,"activeCount":99},[],{"trials":995,"activeCount":99},[],{"intervention":213,"totalTrials":95,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":95,"soonestReadout":45},[1006],{"nctId":43,"briefTitle":44,"status":109,"phases":1007,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":1008,"interventions":1009},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"intervention":214,"totalTrials":95,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":95,"soonestReadout":45},[1024],{"nctId":43,"briefTitle":44,"status":109,"phases":1025,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":1026,"interventions":1027},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":1029,"activeCount":99},[],{"trials":1031,"activeCount":99},[],{"intervention":215,"totalTrials":95,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":95,"soonestReadout":45},[1042],{"nctId":43,"briefTitle":44,"status":109,"phases":1043,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":1044,"interventions":1045},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":1047,"activeCount":99},[],{"trials":1049,"activeCount":99},[],{"intervention":216,"totalTrials":95,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1064,"NA":1066},{"trials":1053,"activeCount":99},[],{"trials":1055,"activeCount":99},[],{"trials":1057,"activeCount":99},[],{"trials":1059,"activeCount":95,"soonestReadout":45},[1060],{"nctId":43,"briefTitle":44,"status":109,"phases":1061,"primaryCompletion":45,"completion":167,"start":168,"enrollment":169,"conditions":1062,"interventions":1063},[90],[171],[46,173,174,175,176,177,178,179,180,181,182,183,184,155,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,189,213,214,215,216],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"intervention":61,"totalTrials":95,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":95,"soonestReadout":60},[1076],{"nctId":58,"briefTitle":59,"status":1077,"phases":1078,"primaryCompletion":60,"completion":1079,"start":1080,"enrollment":9,"conditions":1081,"interventions":1083},"ACTIVE_NOT_RECRUITING",[89],"2029-03-01","2024-03-01",[1082],"Monoclonal Gammopathy of Uncertain Significance",[61],{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[],{"trials":1089,"activeCount":99},[],{"intervention":1091,"totalTrials":95,"cells":1092},"Temozolomide",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":95,"soonestReadout":1104},[1099],{"nctId":1100,"briefTitle":1101,"status":1102,"phases":1103,"primaryCompletion":1104,"completion":1105,"start":1106,"enrollment":1107,"conditions":1108,"interventions":1110},"NCT07562971","Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)","NOT_YET_RECRUITING",[88,89],"2030-11","2031-11","2026-05",20,[1109],"Diffuse Midline Glioma, H3 K27-Altered",[1091],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":95,"soonestReadout":74},[1125],{"nctId":72,"briefTitle":73,"status":109,"phases":1126,"primaryCompletion":74,"completion":1127,"start":1128,"enrollment":1129,"conditions":1130,"interventions":1132},[89],"2028-06","2024-06-18",40,[1131],"Metastatic Colorectal Cancer",[75],{"trials":1134,"activeCount":99},[],{"trials":1136,"activeCount":99},[],{"trials":1138,"activeCount":99},[],{"intervention":51,"totalTrials":95,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1142,"activeCount":99},[],{"trials":1144,"activeCount":99},[],{"trials":1146,"activeCount":95,"soonestReadout":50},[1147],{"nctId":48,"briefTitle":49,"status":109,"phases":1148,"primaryCompletion":50,"completion":50,"start":1149,"enrollment":1107,"conditions":1150,"interventions":1153},[88,89],"2021-10-06",[1151,1152],"Systemic Sclerosis","Digital Ulcer",[51],{"trials":1155,"activeCount":99},[],{"trials":1157,"activeCount":99},[],{"trials":1159,"activeCount":99},[],{"intervention":56,"totalTrials":95,"cells":1161},{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":95,"soonestReadout":55},[1168],{"nctId":53,"briefTitle":54,"status":109,"phases":1169,"primaryCompletion":55,"completion":70,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1176},[89],"2024-03-12",60,[1173,1174,1175],"Behcet's Disease","Idiopathic Inflammatory Myopathies","IgG4-related Disease",[56],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"trials":1182,"activeCount":99},[],{"intervention":85,"totalTrials":95,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":95,"soonestReadout":84},[1189],{"nctId":82,"briefTitle":83,"status":109,"phases":1190,"primaryCompletion":84,"completion":84,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1196},[88],"2024-07-26",24,[1194,1195],"Cancer","Metastatic Cancer",[85],{"trials":1198,"activeCount":99},[],{"trials":1200,"activeCount":99},[],{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":99},[],{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":95,"soonestReadout":79},[1219],{"nctId":77,"briefTitle":78,"status":109,"phases":1220,"primaryCompletion":79,"completion":79,"start":1221,"enrollment":1129,"conditions":1222,"interventions":1224},[],"2025-06-01",[1223],"Prurigo Nodularis (PN)",[80],{"intervention":1226,"totalTrials":123,"cells":1227},"Aliskiren",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1264},{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[],{"trials":1237,"activeCount":99},[1238,1251],{"nctId":1239,"briefTitle":1240,"status":244,"phases":1241,"primaryCompletion":1242,"completion":1242,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1248},"NCT01138423","Treatment of Adiposity Related hypErTension (TARGET)",[91],"2012-02","2010-08",32,[21,1246,1247],"Abdominal Obesity","Metabolic Syndrome",[1226,1249,1250],"Moxonidine","Hydrochlorothiazide",{"nctId":1252,"briefTitle":1253,"status":1254,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1263},"NCT00719316","Aliskiren and Muscle Sympathetic Nerve Activity","UNKNOWN",[91],"2009-07","2010-01","2008-07",30,[1261,21,1262],"Chronic Kidney Disease","Muscle Sympathetic Nerve Activity",[1226],{"trials":1265,"activeCount":99},[],{"intervention":1267,"totalTrials":123,"cells":1268},"Rivastigmine",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1288,"NA":1300},{"trials":1270,"activeCount":99},[],{"trials":1272,"activeCount":99},[],{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[1277],{"nctId":1278,"briefTitle":1279,"status":222,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1285},"NCT00599287","Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients",[90],"2008-05","2008-02",80,[24],[1286,1287,1267],"Haloperidol","Methylphenidate",{"trials":1289,"activeCount":99},[1290],{"nctId":1291,"briefTitle":1292,"status":222,"phases":1293,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1299},"NCT00704301","Rivastigmine for Intensive Care Unit (ICU) Delirium",[91],"2010-04","2010-05","2008-11",104,[24],[1267],{"trials":1301,"activeCount":99},[],{"intervention":1303,"totalTrials":95,"cells":1304},"Salbutamol",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1313,"NA":1325},{"trials":1306,"activeCount":99},[],{"trials":1308,"activeCount":99},[],{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":99},[],{"trials":1314,"activeCount":99},[1315],{"nctId":1316,"briefTitle":1317,"status":1318,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":99,"conditions":1322,"interventions":1324},"NCT04584034","Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial","WITHDRAWN",[91],"2023-04","2021-09",[1323],"Wheezing",[1303],{"trials":1326,"activeCount":99},[],{"intervention":1328,"totalTrials":95,"cells":1329},"Sevoflurane and isoflurane",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1338,"NA":1350},{"trials":1331,"activeCount":99},[],{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[1340],{"nctId":1341,"briefTitle":1342,"status":222,"phases":1343,"primaryCompletion":1344,"completion":1345,"start":1346,"enrollment":22,"conditions":1347,"interventions":1349},"NCT00922844","The Effect of Sevoflurane Versus Isoflurane on Vasopressor Need",[91],"2009-11","2009-12","2009-05",[1348],"Hypotension",[1328],{"trials":1351,"activeCount":99},[],{"intervention":1353,"totalTrials":95,"cells":1354},"trivalent inactivated influenza vaccine",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1376},{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[1365],{"nctId":1366,"briefTitle":1367,"status":244,"phases":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1374},"NCT00161122","Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)",[91],"2006-06","2003-09",660,[1373],"Recurrent Upper and Lower Respiratory Tract Infections (RTIs)",[1353,1375],"combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine",{"trials":1377,"activeCount":99},[],{"intervention":1375,"totalTrials":95,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1394},{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[1390],{"nctId":1366,"briefTitle":1367,"status":244,"phases":1391,"completion":1369,"start":1370,"enrollment":1371,"conditions":1392,"interventions":1393},[91],[1373],[1353,1375],{"trials":1395,"activeCount":99},[],{"intervention":1397,"totalTrials":95,"cells":1398},"anticoagulation",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1423},{"trials":1400,"activeCount":99},[],{"trials":1402,"activeCount":99},[],{"trials":1404,"activeCount":99},[],{"trials":1406,"activeCount":99},[],{"trials":1408,"activeCount":99},[1409],{"nctId":1410,"briefTitle":1411,"status":244,"phases":1412,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1420},"NCT00161070","ESPRIT: European\u002FAustralasian Stroke Prevention in Reversible Ischaemia Trial",[91],"2006-12","1997-07",4500,[1417,1418,1419],"Brain Ischemia","Transient Ischemic Attack","Arteriosclerosis",[1397,1421,1422],"aspirin and dipyridamole","aspirin alone",{"trials":1424,"activeCount":99},[],{"intervention":1421,"totalTrials":95,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1441},{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[1437],{"nctId":1410,"briefTitle":1411,"status":244,"phases":1438,"completion":1413,"start":1414,"enrollment":1415,"conditions":1439,"interventions":1440},[91],[1417,1418,1419],[1397,1421,1422],{"trials":1442,"activeCount":99},[],{"intervention":1422,"totalTrials":95,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1459},{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[1455],{"nctId":1410,"briefTitle":1411,"status":244,"phases":1456,"completion":1413,"start":1414,"enrollment":1415,"conditions":1457,"interventions":1458},[91],[1417,1418,1419],[1397,1421,1422],{"trials":1460,"activeCount":99},[],{"intervention":1462,"totalTrials":95,"cells":1463},"Atorvastatin",{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1472,"NA":1483},{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[1474],{"nctId":1475,"briefTitle":1476,"status":244,"phases":1477,"primaryCompletion":1478,"completion":1478,"start":1479,"enrollment":22,"conditions":1480,"interventions":1482},"NCT01257009","Atorvastatin and Sympathetic Activity in Chronic Kidney Disease",[91],"2010-07","2009-08",[1481,21],"Stable Chronic Kidney Disease",[1462],{"trials":1484,"activeCount":99},[],{"intervention":1486,"totalTrials":95,"cells":1487},"ursodeoxycholic acid",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1508},{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[1498],{"nctId":1499,"briefTitle":1500,"status":244,"phases":1501,"completion":1502,"start":1503,"enrollment":1504,"conditions":1505,"interventions":1507},"NCT00161083","UDCA for Symptomatic Gallstone Disease",[91],"2004-11","2001-11",180,[1506],"Cholecystolithiasis",[1486],{"trials":1509,"activeCount":99},[],{"intervention":1511,"totalTrials":95,"cells":1512},"naratriptan",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1536},{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"trials":1518,"activeCount":99},[],{"trials":1520,"activeCount":99},[],{"trials":1522,"activeCount":99},[1523],{"nctId":1524,"briefTitle":1525,"status":222,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1535},"NCT00282165","Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order",[91],"2012-12","2006-11",8,[1531,1532,1533,1534],"Psychotic Disorders","Antisocial Personality Disorder","Impulse Regulation Disorder","Intermittent Explosive Disorder",[1511],{"trials":1537,"activeCount":99},[],{"intervention":1539,"totalTrials":95,"cells":1540},"raltegravir",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1562},{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[],{"trials":1546,"activeCount":99},[],{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[1551],{"nctId":1552,"briefTitle":1553,"status":1254,"phases":1554,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1192,"conditions":1558,"interventions":1561},"NCT01453933","RAltegravir Switch STudy: Effects on Endothelial Recovery",[91],"2014-10","2014-12","2012-01",[1559,1560],"HIV Infection","Endothelial Dysfunction",[1539],{"trials":1563,"activeCount":99},[],{"intervention":1249,"totalTrials":95,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1580},{"trials":1567,"activeCount":99},[],{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[1576],{"nctId":1239,"briefTitle":1240,"status":244,"phases":1577,"primaryCompletion":1242,"completion":1242,"start":1243,"enrollment":1244,"conditions":1578,"interventions":1579},[91],[21,1246,1247],[1226,1249,1250],{"trials":1581,"activeCount":99},[],{"intervention":1250,"totalTrials":95,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1590,"PHASE4":1592,"NA":1598},{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[],{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[1594],{"nctId":1239,"briefTitle":1240,"status":244,"phases":1595,"primaryCompletion":1242,"completion":1242,"start":1243,"enrollment":1244,"conditions":1596,"interventions":1597},[91],[21,1246,1247],[1226,1249,1250],{"trials":1599,"activeCount":99},[],{"intervention":1601,"totalTrials":95,"cells":1602},"Aripiprazole",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1609,"PHASE4":1611,"NA":1626},{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[],{"trials":1612,"activeCount":99},[1613],{"nctId":1614,"briefTitle":1615,"status":244,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1622},"NCT02146547","European Long-acting Antipsychotics in Schizophrenia Trial",[91],"2020-08-26","2015-02",536,[1621],"Schizophrenia",[1601,1623,1624,1625],"Aripiprazole depot","Paliperidone","Paliperidone palmitate",{"trials":1627,"activeCount":99},[],{"intervention":1623,"totalTrials":95,"cells":1629},{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1638,"NA":1644},{"trials":1631,"activeCount":99},[],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"trials":1639,"activeCount":99},[1640],{"nctId":1614,"briefTitle":1615,"status":244,"phases":1641,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1642,"interventions":1643},[91],[1621],[1601,1623,1624,1625],{"trials":1645,"activeCount":99},[],{"intervention":1624,"totalTrials":95,"cells":1647},{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1654,"PHASE4":1656,"NA":1662},{"trials":1649,"activeCount":99},[],{"trials":1651,"activeCount":99},[],{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[1658],{"nctId":1614,"briefTitle":1615,"status":244,"phases":1659,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1660,"interventions":1661},[91],[1621],[1601,1623,1624,1625],{"trials":1663,"activeCount":99},[],{"intervention":1625,"totalTrials":95,"cells":1665},{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1672,"PHASE4":1674,"NA":1680},{"trials":1667,"activeCount":99},[],{"trials":1669,"activeCount":99},[],{"trials":1671,"activeCount":99},[],{"trials":1673,"activeCount":99},[],{"trials":1675,"activeCount":99},[1676],{"nctId":1614,"briefTitle":1615,"status":244,"phases":1677,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1678,"interventions":1679},[91],[1621],[1601,1623,1624,1625],{"trials":1681,"activeCount":99},[],{"intervention":1683,"totalTrials":95,"cells":1684},"simvastatin and ezetimibe",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1693,"NA":1703},{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[1695],{"nctId":1696,"briefTitle":1697,"status":244,"phases":1698,"completion":1699,"start":1700,"enrollment":1107,"conditions":1701,"interventions":1702},"NCT00189085","Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function",[91],"2005-07","2004-12",[1247],[1683],{"trials":1704,"activeCount":99},[],{"intervention":1706,"totalTrials":95,"cells":1707},"Rivastigmine Transdermal Product",{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1714,"PHASE4":1716,"NA":1728},{"trials":1709,"activeCount":99},[],{"trials":1711,"activeCount":99},[],{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[1718],{"nctId":1719,"briefTitle":1720,"status":1254,"phases":1721,"primaryCompletion":40,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1727},"NCT05768126","Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine",[91],"2026-01","2021-09-29",100,[1726],"Depressive Disorder",[1706],{"trials":1729,"activeCount":99},[],{"intervention":1731,"totalTrials":95,"cells":1732},"gabapentin",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1751},{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[1743],{"nctId":1744,"briefTitle":1745,"status":222,"phases":1746,"start":1747,"enrollment":1192,"conditions":1748,"interventions":1750},"NCT00189072","Effects of Gabapentin in the Treatment of Neuropathic Pain on Driving Performance and Cognition",[91],"2003-04",[1749],"Chronic Neuropathic Pain",[1731],{"trials":1752,"activeCount":99},[],{"intervention":1754,"totalTrials":95,"cells":1755},"All registered antiepileptic drugs",{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1760,"PHASE3":1762,"PHASE4":1764,"NA":1776},{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[],{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":99},[1766],{"nctId":1767,"briefTitle":1768,"status":1254,"phases":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1775},"NCT00133081","Study to Improve the Treatment of Epilepsy (SITE)",[91],"2006-08","2002-10",255,[1774],"Epilepsy",[1754],{"trials":1777,"activeCount":99},[],{"intervention":1779,"totalTrials":95,"cells":1780},"Mild stimulation",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1802},{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[1791],{"nctId":1792,"briefTitle":1793,"status":222,"phases":1794,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":1797,"conditions":1798,"interventions":1801},"NCT00823472","Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)",[91],"2010-10","2009-01",147,[1799,1800],"in Vitro Fertilization","Ovulation Induction",[1779],{"trials":1803,"activeCount":99},[],{"intervention":1805,"totalTrials":95,"cells":1806},"amitriptyline",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1824},{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[],{"trials":1814,"activeCount":99},[],{"trials":1816,"activeCount":99},[1817],{"nctId":1818,"briefTitle":1819,"status":222,"phases":1820,"completion":1821,"start":1771,"enrollment":1192,"conditions":1822,"interventions":1823},"NCT00189059","Effects of Amitriptyline for the Treatment of Pain on Driving Performance and Cognition.",[91],"2005-05",[1749],[1805],{"trials":1825,"activeCount":99},[],{"intervention":1827,"totalTrials":95,"cells":1828},"Evolocumab Auto-Injector [Repatha]",{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1835,"PHASE4":1837,"NA":1851},{"trials":1830,"activeCount":99},[],{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[],{"trials":1836,"activeCount":99},[],{"trials":1838,"activeCount":99},[1839],{"nctId":1840,"briefTitle":1841,"status":1254,"phases":1842,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":1259,"conditions":1846,"interventions":1849},"NCT03811223","Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia",[91],"2021-01","2021-03","2019-08",[1847,1848],"Familial Dysbetalipoproteinemia","Hyperlipoproteinemia Type III",[1827,1850],"Placebos",{"trials":1852,"activeCount":99},[],{"intervention":1850,"totalTrials":95,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1869},{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[1865],{"nctId":1840,"briefTitle":1841,"status":1254,"phases":1866,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":1259,"conditions":1867,"interventions":1868},[91],[1847,1848],[1827,1850],{"trials":1870,"activeCount":99},[],{"intervention":1872,"totalTrials":95,"cells":1873},"Eviplera",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1894},{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[],{"trials":1881,"activeCount":99},[],{"trials":1883,"activeCount":99},[1884],{"nctId":1885,"briefTitle":1886,"status":244,"phases":1887,"primaryCompletion":1888,"completion":1888,"start":1618,"enrollment":1889,"conditions":1890,"interventions":1893},"NCT02308332","Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning",[91],"2017-06",58,[1891,1892],"Neurocognitive Decline","HIV Associated Neurocognitive Disorder",[1872],{"trials":1895,"activeCount":99},[],{"intervention":1897,"totalTrials":95,"cells":1898},"Bacille Calmette-Guérin",{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1905,"PHASE4":1907,"NA":1920},{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[1909],{"nctId":1910,"briefTitle":1911,"status":244,"phases":1912,"primaryCompletion":1913,"completion":1913,"start":1914,"enrollment":1915,"conditions":1916,"interventions":1919},"NCT04537663","Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults",[91],"2021-07-08","2020-09-07",6112,[1917,1918],"Respiratory Tract Infections","Covid19",[1897],{"trials":1921,"activeCount":99},[],{"intervention":230,"totalTrials":95,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1938},{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[1934],{"nctId":220,"briefTitle":221,"status":222,"phases":1935,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":1936,"interventions":1937},[91],[228],[230,155],{"trials":1939,"activeCount":99},[],{"intervention":1941,"totalTrials":95,"cells":1942},"Prednisolone",{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1949,"PHASE4":1951,"NA":1965},{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"trials":1950,"activeCount":99},[],{"trials":1952,"activeCount":99},[1953],{"nctId":1954,"briefTitle":1955,"status":222,"phases":1956,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":1959,"conditions":1960,"interventions":1964},"NCT02949232","Prednisolone Addition for Patients With Recent-onset Psychotic Disorder",[91],"2019-05","2014-07",42,[1621,1961,1962,1963],"Schizoaffective Disorder","Schizophreniform Disorder","Psychotic Disorder NOS",[1941],{"trials":1966,"activeCount":99},[],{"intervention":1968,"totalTrials":95,"cells":1969},"C1-esterase inhibitor",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1989,"NA":1991},{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[1978],{"nctId":1979,"briefTitle":1980,"status":222,"phases":1981,"primaryCompletion":1618,"completion":1618,"start":1982,"enrollment":19,"conditions":1983,"interventions":1988},"NCT01275976","Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture",[90],"2012-04",[1984,1985,1986,1987],"Trauma","Inflammation","Sepsis","Multiple Organ Dysfunction Syndrome",[1968],{"trials":1990,"activeCount":99},[],{"trials":1992,"activeCount":99},[],{"intervention":1994,"totalTrials":95,"cells":1995},"Hyperbaric oxygen therapy",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2014,"NA":2016},{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[2004],{"nctId":2005,"briefTitle":2006,"status":244,"phases":2007,"primaryCompletion":2008,"completion":2008,"start":2009,"enrollment":2010,"conditions":2011,"interventions":2013},"NCT04193722","The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial",[90],"2023-05-08","2019-08-28",189,[15,2012],"Radiation Toxicity",[1994],{"trials":2015,"activeCount":99},[],{"trials":2017,"activeCount":99},[],{"intervention":2019,"totalTrials":95,"cells":2020},"Induced hypertension with norepinephrine",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2040,"NA":2042},{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[2029],{"nctId":2030,"briefTitle":2031,"status":222,"phases":2032,"primaryCompletion":2033,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2039},"NCT00841633","Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study",[90],"2011-04","2009-02",15,[2037,2038],"Cerebral Ischemia","Subarachnoid Hemorrhage",[2019],{"trials":2041,"activeCount":99},[],{"trials":2043,"activeCount":99},[],{"intervention":2045,"totalTrials":95,"cells":2046},"Sodium Valproate",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2065,"NA":2067},{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[2055],{"nctId":2056,"briefTitle":2057,"status":244,"phases":2058,"completion":2059,"start":2060,"enrollment":2061,"conditions":2062,"interventions":2064},"NCT00136110","Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis",[90],"2007-02","2005-04",165,[2063],"Amyotrophic Lateral Sclerosis",[2045],{"trials":2066,"activeCount":99},[],{"trials":2068,"activeCount":99},[],{"intervention":2070,"totalTrials":95,"cells":2071},"Erythropoietin administration",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2078,"PHASE4":2091,"NA":2093},{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"trials":2079,"activeCount":99},[2080],{"nctId":2081,"briefTitle":2082,"status":244,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2085,"enrollment":2086,"conditions":2087,"interventions":2090},"NCT00356733","Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome",[90],"2011-07","2007-01",62,[2088,2089],"Heart Failure, Congestive","Renal Insufficiency, Chronic",[2070],{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[],{"intervention":2096,"totalTrials":95,"cells":2097},"Probiotics",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2116,"NA":2118},{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[2106],{"nctId":2107,"briefTitle":2108,"status":1254,"phases":2109,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2115},"NCT00161148","Probiotics in Patients With Primary Sclerosing Cholangitis",[90],"2006-05","2005-01",12,[2114],"Primary Sclerosing Cholangitis",[2096],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"intervention":2121,"totalTrials":95,"cells":2122},"lidocaine hydrochloride 5mg\u002Fg",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2142,"NA":2144},{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"trials":2130,"activeCount":99},[2131],{"nctId":2132,"briefTitle":2133,"status":222,"phases":2134,"primaryCompletion":2135,"completion":2136,"start":1149,"enrollment":2137,"conditions":2138,"interventions":2141},"NCT05651633","Analgesic Ear Drops for Children With Acute Otitis Media",[90],"2023-12-16","2024-01-10",29,[2139,2140],"Acute Otitis Media","Pain",[2121],{"trials":2143,"activeCount":99},[],{"trials":2145,"activeCount":99},[],{"intervention":2147,"totalTrials":95,"cells":2148},"BCG Vaccine",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2166,"NA":2168},{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[2157],{"nctId":2158,"briefTitle":2159,"status":244,"phases":2160,"primaryCompletion":2161,"completion":2161,"start":2162,"enrollment":2163,"conditions":2164,"interventions":2165},"NCT04328441","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine",[90],"2021-03-31","2020-03-25",1511,[228],[2147],{"trials":2167,"activeCount":99},[],{"trials":2169,"activeCount":99},[],{"intervention":2171,"totalTrials":95,"cells":2172},"Amantadine",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2190,"NA":2192},{"trials":2174,"activeCount":99},[],{"trials":2176,"activeCount":99},[],{"trials":2178,"activeCount":99},[],{"trials":2180,"activeCount":99},[2181],{"nctId":2182,"briefTitle":2183,"status":244,"phases":2184,"completion":2085,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2189},"NCT00146016","Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients",[90],"2000-02",390,[2188],"Chronic Hepatitis C",[2171],{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[],{"intervention":2195,"totalTrials":95,"cells":2196},"Gallium-68-tilmanocept",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2215,"NA":2217},{"trials":2198,"activeCount":99},[],{"trials":2200,"activeCount":99},[],{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[2205],{"nctId":2206,"briefTitle":2207,"status":1254,"phases":2208,"primaryCompletion":2209,"completion":2210,"start":2211,"enrollment":22,"conditions":2212,"interventions":2214},"NCT05446324","Feasibility of Gallium-68-tilmanocept PET\u002FCT for Sentinel Lymph Node Detection in Endometrial Cancer",[90],"2024-07-01","2024-09-01","2023-02-15",[2213],"Endometrial Cancer",[2195],{"trials":2216,"activeCount":99},[],{"trials":2218,"activeCount":99},[],{"intervention":2220,"totalTrials":95,"cells":2221},"Alendronate versus alfacalcidol",{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2228,"PHASE4":2244,"NA":2246},{"trials":2223,"activeCount":99},[],{"trials":2225,"activeCount":99},[],{"trials":2227,"activeCount":99},[],{"trials":2229,"activeCount":99},[2230],{"nctId":2231,"briefTitle":2232,"status":244,"phases":2233,"completion":2234,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2243},"NCT00138983","Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.",[90],"2003-11","2000-05",200,[2238,2239,2240,2241,2242],"Rheumatoid Arthritis","Polymyalgia Rheumatica","Giant Cell Arteritis","Polymyositis","Wegener's Granulomatosis",[2220],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"intervention":1286,"totalTrials":95,"cells":2249},{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2262,"NA":2264},{"trials":2251,"activeCount":99},[],{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[2258],{"nctId":1278,"briefTitle":1279,"status":222,"phases":2259,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":2260,"interventions":2261},[90],[24],[1286,1287,1267],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"intervention":1287,"totalTrials":95,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2280,"NA":2282},{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[2276],{"nctId":1278,"briefTitle":1279,"status":222,"phases":2277,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":2278,"interventions":2279},[90],[24],[1286,1287,1267],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"intervention":2285,"totalTrials":95,"cells":2286},"Allopurinol sodium",{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2293,"PHASE4":2308,"NA":2310},{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":99},[],{"trials":2292,"activeCount":99},[],{"trials":2294,"activeCount":99},[2295],{"nctId":2296,"briefTitle":2297,"status":1254,"phases":2298,"primaryCompletion":2299,"completion":2300,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2306},"NCT00189007","Antenatal Allopurinol During Fetal Hypoxia",[90],"2011-12","2016-12","2009-10",222,[2304,2305],"Fetal Hypoxia","Reperfusion Injury",[2285,2307],"Mannitol",{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[],{"intervention":2307,"totalTrials":95,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2326,"NA":2328},{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[],{"trials":2321,"activeCount":99},[2322],{"nctId":2296,"briefTitle":2297,"status":1254,"phases":2323,"primaryCompletion":2299,"completion":2300,"start":2301,"enrollment":2302,"conditions":2324,"interventions":2325},[90],[2304,2305],[2285,2307],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"intervention":2331,"totalTrials":95,"cells":2332},"Dexamethasone acetate",{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2349,"NA":2351},{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"trials":2340,"activeCount":99},[2341],{"nctId":2342,"briefTitle":2343,"status":244,"phases":2344,"primaryCompletion":280,"completion":280,"start":1557,"enrollment":2345,"conditions":2346,"interventions":2348},"NCT01669499","Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009",[90],411,[2347],"Bone Metastases",[2331],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[],{"intervention":2354,"totalTrials":95,"cells":2355},"PCV7",{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2362,"PHASE4":2373,"NA":2375},{"trials":2357,"activeCount":99},[],{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[2364],{"nctId":2365,"briefTitle":2366,"status":244,"phases":2367,"primaryCompletion":1282,"start":2368,"enrollment":2369,"conditions":2370,"interventions":2372},"NCT00189020","Effect of Two Versus Three Pneumococcal Conjugate Vaccinations",[90],"2005-06",1005,[2371],"Streptococcus Pneumoniae Infection",[2354,2354],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":99},[],{"intervention":2378,"totalTrials":95,"cells":2379},"pantoprazole 20 mg",{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2402,"NA":2404},{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[2388],{"nctId":2389,"briefTitle":2390,"status":1254,"phases":2391,"completion":2392,"start":2393,"enrollment":2394,"conditions":2395,"interventions":2401},"NCT00161096","On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication",[90],"2005-09","2004-03",276,[2396,2397,2398,2399,2400],"Chronic Use of Acid Suppressive Medication","GORD","GERD","Reflux","Peptic Ulcer",[2378],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[],{"intervention":2407,"totalTrials":95,"cells":2408},"Combined aspirin and multinutrient supplement",{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2428,"NA":2430},{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[],{"trials":2414,"activeCount":99},[],{"trials":2416,"activeCount":99},[2417],{"nctId":2418,"briefTitle":2419,"status":1254,"phases":2420,"primaryCompletion":2421,"completion":2422,"start":2423,"enrollment":2424,"conditions":2425,"interventions":2427},"NCT02007837","Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial",[90],"2018-04","2018-08","2018-01",440,[2426],"Pregnancy Induced Hypertension",[2407],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[],{"intervention":2433,"totalTrials":95,"cells":2434},"Standard of care first-line systemic therapy",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2436,"activeCount":99},[],{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[2441],{"nctId":2442,"briefTitle":2443,"status":222,"phases":2444,"primaryCompletion":2445,"completion":2445,"start":2446,"enrollment":2447,"conditions":2448,"interventions":2450},"NCT05092880","Radioembolization in Elderly\u002F Fragile Patients With mCRC",[89],"2025-09-01","2022-06-01",18,[2449],"Colorectal Cancer Metastatic",[2433],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"trials":2456,"activeCount":99},[],{"intervention":2458,"totalTrials":95,"cells":2459},"Mesenchymal Stem Cells",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[2466],{"nctId":2467,"briefTitle":2468,"status":244,"phases":2469,"primaryCompletion":2470,"completion":2470,"start":2471,"enrollment":22,"conditions":2472,"interventions":2475},"NCT03356821","Perinatal Arterial Stroke Treated With Stromal Cells Intranasally",[88,89],"2021-07-27","2020-02-11",[2473,2474],"Perinatal Arterial Ischemic Stroke","Neonatal Stroke",[2458],{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"intervention":253,"totalTrials":95,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"trials":2489,"activeCount":99},[2490],{"nctId":242,"briefTitle":243,"status":244,"phases":2491,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":2492,"interventions":2493},[89],[250,251],[253,199,254,255,256],{"trials":2495,"activeCount":99},[],{"trials":2497,"activeCount":99},[],{"trials":2499,"activeCount":99},[],{"intervention":254,"totalTrials":95,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[],{"trials":2507,"activeCount":99},[2508],{"nctId":242,"briefTitle":243,"status":244,"phases":2509,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":2510,"interventions":2511},[89],[250,251],[253,199,254,255,256],{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"intervention":255,"totalTrials":95,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[2526],{"nctId":242,"briefTitle":243,"status":244,"phases":2527,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":2528,"interventions":2529},[89],[250,251],[253,199,254,255,256],{"trials":2531,"activeCount":99},[],{"trials":2533,"activeCount":99},[],{"trials":2535,"activeCount":99},[],{"intervention":256,"totalTrials":95,"cells":2537},{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2539,"activeCount":99},[],{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[2544],{"nctId":242,"briefTitle":243,"status":244,"phases":2545,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":2546,"interventions":2547},[89],[250,251],[253,199,254,255,256],{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"intervention":2555,"totalTrials":95,"cells":2556},"Ofloxacinum\u002FDoxycycline",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2558,"activeCount":99},[],{"trials":2560,"activeCount":99},[],{"trials":2562,"activeCount":99},[2563],{"nctId":2564,"briefTitle":2565,"status":222,"phases":2566,"primaryCompletion":1296,"completion":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2572},"NCT00830401","The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases",[89],"2009-03","2007-06",700,[2571],"Minor Intra-uterine Abnormalities",[2555],{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[],{"intervention":2580,"totalTrials":95,"cells":2581},"Pyridostigmine",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":99},[2588],{"nctId":2589,"briefTitle":2590,"status":244,"phases":2591,"primaryCompletion":2423,"completion":2423,"start":2592,"enrollment":2593,"conditions":2594,"interventions":2598},"NCT02941328","SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4",[89],"2015-12",39,[2595,2596,2597],"Spinal Muscular Atrophy","SMA","Kugelberg-Welander Disease",[2580],{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[],{"trials":2604,"activeCount":99},[],{"intervention":2606,"totalTrials":95,"cells":2607},"Darbepoetin Alfa",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2625,"PHASE4":2627,"NA":2629},{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[],{"trials":2613,"activeCount":99},[2614],{"nctId":2615,"briefTitle":2616,"status":1254,"phases":2617,"primaryCompletion":2618,"completion":1221,"start":2619,"enrollment":1283,"conditions":2620,"interventions":2623},"NCT03171818","Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration",[89],"2024-12-31","2017-07-01",[2621,2474,2622],"PAIS","Perinatal Stroke",[2606,2624],"Saline",{"trials":2626,"activeCount":99},[],{"trials":2628,"activeCount":99},[],{"trials":2630,"activeCount":99},[],{"intervention":2624,"totalTrials":95,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2643,"PHASE4":2645,"NA":2647},{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[],{"trials":2638,"activeCount":99},[2639],{"nctId":2615,"briefTitle":2616,"status":1254,"phases":2640,"primaryCompletion":2618,"completion":1221,"start":2619,"enrollment":1283,"conditions":2641,"interventions":2642},[89],[2621,2474,2622],[2606,2624],{"trials":2644,"activeCount":99},[],{"trials":2646,"activeCount":99},[],{"trials":2648,"activeCount":99},[],{"intervention":2650,"totalTrials":95,"cells":2651},"combined radiotherapy and MR-HIFU",{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"trials":2657,"activeCount":99},[2658],{"nctId":2659,"briefTitle":2660,"status":244,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":22,"conditions":2665,"interventions":2673},"NCT04310410","Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis",[88,89],"2020-04-01","2020-06-01","2019-04-11",[2347,2666,2667,2668,2140,2669,2012,2670,2671,2672],"Bone Neoplasm","Bone Lesion","Bone Cancer","Cancer Induced Bone Pain","Quality of Life","Tumor","Neoplasm Metastasis",[2650],{"trials":2675,"activeCount":99},[],{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[],{"intervention":2681,"totalTrials":95,"cells":2682},"Lenalidomide, endoxan, prednisone",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2701,"PHASE4":2703,"NA":2705},{"trials":2684,"activeCount":99},[],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[2689],{"nctId":2690,"briefTitle":2691,"status":244,"phases":2692,"primaryCompletion":2693,"completion":2694,"start":2695,"enrollment":2696,"conditions":2697,"interventions":2699},"NCT01352338","Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)",[88,89],"2014-11","2016-02","2011-08",82,[2698],"Multiple Myeloma",[2681,2700],"lenalidomide, endoxan, prednisone",{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[],{"trials":2706,"activeCount":99},[],{"intervention":2708,"totalTrials":95,"cells":2709},"Maintenance therapy",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2728,"PHASE4":2730,"NA":2732},{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[],{"trials":2715,"activeCount":99},[2716],{"nctId":2717,"briefTitle":2718,"status":2719,"phases":2720,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":2725,"interventions":2727},"NCT05375708","Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","SUSPENDED",[89],"2031-06-01","2034-06-01","2025-12-01",93,[1131,2726],"Oligometastatic Disease",[2708],{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"intervention":2735,"totalTrials":95,"cells":2736},"Dehydroepiandrosterone",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[2743],{"nctId":2744,"briefTitle":2745,"status":244,"phases":2746,"completion":2747,"start":2235,"enrollment":2748,"conditions":2749,"interventions":2752},"NCT00391924","Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome",[89],"2003-01",120,[2750,2751],"Lupus Erythematosus, Systemic","Sjogren's Syndrome",[2735],{"trials":2754,"activeCount":99},[],{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[],{"intervention":2760,"totalTrials":95,"cells":2761},"autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70",{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2777,"PHASE4":2779,"NA":2781},{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[2768],{"nctId":2769,"briefTitle":2770,"status":1254,"phases":2771,"primaryCompletion":2772,"completion":2773,"start":2774,"enrollment":2447,"conditions":2775,"interventions":2776},"NCT05251870","Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis",[88,89],"2024-08","2025-08","2021-08-17",[2238],[2760],{"trials":2778,"activeCount":99},[],{"trials":2780,"activeCount":99},[],{"trials":2782,"activeCount":99},[],{"intervention":2784,"totalTrials":95,"cells":2785},"Mesalazine",{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2802,"PHASE4":2804,"NA":2806},{"trials":2787,"activeCount":99},[],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[2792],{"nctId":2793,"briefTitle":2794,"status":244,"phases":2795,"primaryCompletion":2796,"completion":2796,"start":2797,"enrollment":2798,"conditions":2799,"interventions":2801},"NCT01894685","Mesalazine Effects in Sporadic Colorectal Adenoma Patients",[89],"2015-06","2012-07",74,[2800],"Sporadic Colorectal Adenoma",[2784],{"trials":2803,"activeCount":99},[],{"trials":2805,"activeCount":99},[],{"trials":2807,"activeCount":99},[],{"intervention":2809,"totalTrials":95,"cells":2810},"Delta9-tetrahydrocannabinol",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[2815],{"nctId":2816,"briefTitle":2817,"status":244,"phases":2818,"primaryCompletion":2819,"completion":2819,"start":2820,"enrollment":2112,"conditions":2821,"interventions":2827},"NCT00628706","Investigating the Acute Effects of THC on Functional Brain Systems",[88],"2008-09","2008-04",[2822,2823,2824,2825,2826],"Reward","Tetrahydrocannabinol","Endocannabinoids","Memory","Magnetic Resonance Imaging",[2809],{"trials":2829,"activeCount":99},[],{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"intervention":2837,"totalTrials":95,"cells":2838},"Smoking of cannabis cigarettes",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2852,"PHASE3":2854,"PHASE4":2856,"NA":2858},{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[2843],{"nctId":2844,"briefTitle":2845,"status":1254,"phases":2846,"completion":2847,"start":1699,"enrollment":2848,"conditions":2849,"interventions":2851},"NCT00225407","Processing and Effects of Cannabis",[88],"2005-12",27,[1348,2850],"Tachycardia",[2837],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[],{"trials":2859,"activeCount":99},[],{"intervention":2861,"totalTrials":95,"cells":2862},"Indomethacin",{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2879,"PHASE3":2881,"PHASE4":2883,"NA":2885},{"trials":2864,"activeCount":99},[],{"trials":2866,"activeCount":99},[2867],{"nctId":2868,"briefTitle":2869,"status":244,"phases":2870,"primaryCompletion":2871,"completion":2871,"start":2872,"enrollment":2873,"conditions":2874,"interventions":2878},"NCT01719926","Phase I Platinum Based Chemotherapy Plus Indomethacin",[88],"2017-08","2012-09",13,[2875,2876,2877],"Colorectal Neoplasms","Esophageal Neoplasms","Ovarian Neoplasms",[2861],{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[],{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"intervention":2888,"totalTrials":95,"cells":2889},"LTLD",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2908,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[2894],{"nctId":2895,"briefTitle":2896,"status":1254,"phases":2897,"primaryCompletion":2898,"completion":2898,"start":1844,"enrollment":2112,"conditions":2899,"interventions":2906},"NCT03749850","Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer",[88],"2022-11",[2900,15,2901,2902,1195,2903,2904,2905],"Metastatic Breast Cancer","Breast Neoplasms","Stage IV Breast Cancer","Invasive Ductal Carcinoma of Female Breast","Invasive Ductal Breast Cancer","Adenocarcinoma Breast",[2888,2907],"Cyclophosphamide",{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"intervention":2907,"totalTrials":95,"cells":2917},{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2926,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[2922],{"nctId":2895,"briefTitle":2896,"status":1254,"phases":2923,"primaryCompletion":2898,"completion":2898,"start":1844,"enrollment":2112,"conditions":2924,"interventions":2925},[88],[2900,15,2901,2902,1195,2903,2904,2905],[2888,2907],{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"intervention":2935,"totalTrials":123,"cells":2936},"Dexamethasone",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2956},{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[2947],{"nctId":2948,"briefTitle":2949,"status":244,"phases":2950,"primaryCompletion":2951,"completion":1557,"start":2952,"enrollment":1283,"conditions":2953,"interventions":2955},"NCT01143129","Postoperative New-onset Atrial Fibrillation in Cardiac Surgery: DECS-PNAF Project",[91],"2011-11","2011-01",[251,2954],"Cardiac Surgery",[2935],{"trials":2957,"activeCount":99},[2958],{"nctId":2959,"briefTitle":2960,"status":244,"phases":2961,"primaryCompletion":2951,"completion":1527,"start":2110,"enrollment":1415,"conditions":2962,"interventions":2966},"NCT00293592","Dexamethasone for Cardiac Surgery Trial",[92],[2963,2964,2965],"Systemic Inflammatory Response Syndrome","Cardiac Diseases","Postoperative Complications",[2935],{"intervention":2968,"totalTrials":95,"cells":2969},"Allopurinol",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[],{"trials":2975,"activeCount":99},[],{"trials":2977,"activeCount":99},[],{"trials":2979,"activeCount":99},[],{"trials":2981,"activeCount":99},[2982],{"nctId":2983,"briefTitle":2984,"status":1254,"phases":2985,"completion":2986,"start":2987,"enrollment":2988,"conditions":2989,"interventions":2991},"NCT00346463","Antenatal Allopurinol in Intrauterine Growth Restriction",[92],"2013-07","2006-07",50,[2990],"Fetal Growth Retardation",[2968],{"intervention":2993,"totalTrials":95,"cells":2994},"Cardiovascular Agents",{"EARLY_PHASE1":2995,"PHASE1":2997,"PHASE2":2999,"PHASE3":3001,"PHASE4":3003,"NA":3005},{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[],{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":99},[],{"trials":3004,"activeCount":99},[],{"trials":3006,"activeCount":99},[3007],{"nctId":3008,"briefTitle":3009,"status":244,"phases":3010,"primaryCompletion":2986,"completion":2986,"start":2797,"enrollment":3011,"conditions":3012,"interventions":3016},"NCT01506505","The Evening Versus Morning Polypill Utilization Study",[92],78,[3013,3014,3015],"Cardiovascular Disease","Cerebrovascular Disease","Peripheral Arterial Disease",[2993],{"intervention":3018,"totalTrials":95,"cells":3019},"Sulfamethoxazole-trimethoprim",{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3021,"activeCount":99},[],{"trials":3023,"activeCount":99},[],{"trials":3025,"activeCount":99},[],{"trials":3027,"activeCount":99},[],{"trials":3029,"activeCount":99},[],{"trials":3031,"activeCount":99},[3032],{"nctId":3033,"briefTitle":3034,"status":244,"phases":3035,"primaryCompletion":1369,"completion":1528,"start":3036,"enrollment":248,"conditions":3037,"interventions":3039},"NCT00189098","Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media",[92],"2003-02",[3038],"Chronic Otitis Media",[3018],{"intervention":3041,"totalTrials":95,"cells":3042},"rosuvastatin",{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3044,"activeCount":99},[],{"trials":3046,"activeCount":99},[],{"trials":3048,"activeCount":99},[],{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[3055],{"nctId":3056,"briefTitle":3057,"status":1318,"phases":3058,"primaryCompletion":3059,"completion":3059,"start":3060,"enrollment":99,"conditions":3061,"interventions":3063},"NCT00371579","Rosuvastatin for Hepatitis C",[92],"2007-10","2006-10",[3062],"Hepatitis C",[3041],{"intervention":3065,"totalTrials":95,"cells":3066},"Everolimus",{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3073,"PHASE4":3075,"NA":3077},{"trials":3068,"activeCount":99},[],{"trials":3070,"activeCount":99},[],{"trials":3072,"activeCount":99},[],{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":99},[3079],{"nctId":3080,"briefTitle":3081,"status":244,"phases":3082,"primaryCompletion":3083,"completion":3084,"start":3085,"enrollment":3086,"conditions":3087,"interventions":3089},"NCT01566279","A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)",[92],"2015-11","2016-11","2012-08",73,[3088],"Unspecified Adult Solid Tumor, Protocol Specific",[3065],{"intervention":3091,"totalTrials":95,"cells":3092},"Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[],{"trials":3098,"activeCount":99},[],{"trials":3100,"activeCount":99},[],{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[3105],{"nctId":3106,"briefTitle":3107,"status":222,"phases":3108,"primaryCompletion":3109,"completion":3110,"start":3111,"enrollment":3112,"conditions":3113,"interventions":3117},"NCT04506372","Management of Angiotensin Inhibitors During the Perioperative Period",[92],"2023-02-06","2023-09-01","2020-09-11",342,[3114,3115,3116],"Surgery","Angiotensin Hypertension","Perioperative Complication",[3091],{"intervention":3119,"totalTrials":95,"cells":3120},"menaquinone 7",{"EARLY_PHASE1":3121,"PHASE1":3123,"PHASE2":3125,"PHASE3":3127,"PHASE4":3129,"NA":3131},{"trials":3122,"activeCount":99},[],{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":99},[],{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[3133],{"nctId":3134,"briefTitle":3135,"status":244,"phases":3136,"completion":3137,"start":2085,"enrollment":11,"conditions":3138,"interventions":3140},"NCT00402974","The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children",[92],"2007-04",[3139],"Healthy",[3119],{"intervention":3142,"totalTrials":95,"cells":3143},"Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3145,"activeCount":99},[],{"trials":3147,"activeCount":99},[],{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":99},[],{"trials":3153,"activeCount":99},[],{"trials":3155,"activeCount":99},[3156],{"nctId":3157,"briefTitle":3158,"status":1254,"phases":3159,"primaryCompletion":3160,"completion":3161,"start":3162,"enrollment":3163,"conditions":3164,"interventions":3167},"NCT05145348","Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.",[],"2022-06-30","2023-06-30","2021-02-03",640,[3165,3166],"Down Syndrome","SARS-CoV-2 Vaccination",[3142],{"intervention":3169,"totalTrials":95,"cells":3170},"Cannabidiol",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":99},[],{"trials":3182,"activeCount":99},[3183],{"nctId":3184,"briefTitle":3185,"status":244,"phases":3186,"primaryCompletion":3187,"completion":3187,"start":3188,"enrollment":1244,"conditions":3189,"interventions":3190},"NCT02932605","Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia",[92],"2020-01-31","2017-11-03",[1621],[3169],{"intervention":3192,"totalTrials":95,"cells":3193},"Extended release tacrolimus",{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3198,"PHASE3":3200,"PHASE4":3202,"NA":3204},{"trials":3195,"activeCount":99},[],{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"trials":3201,"activeCount":99},[],{"trials":3203,"activeCount":99},[],{"trials":3205,"activeCount":99},[3206],{"nctId":3207,"briefTitle":3208,"status":244,"phases":3209,"primaryCompletion":3210,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3215},"NCT01789619","Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients",[],"2014-01","2012-10",9,[3214],"Atopic Dermatitis",[3192],{"intervention":3217,"totalTrials":95,"cells":3218},"rHuPH20",{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3220,"activeCount":99},[],{"trials":3222,"activeCount":99},[],{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[],{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[3231],{"nctId":3232,"briefTitle":3233,"status":1254,"phases":3234,"primaryCompletion":3235,"completion":2423,"start":3236,"enrollment":1107,"conditions":3237,"interventions":3239},"NCT02885259","HyQvia in Multifocal Motor Neuropathy",[92],"2017-12","2016-09",[3238],"Multifocal Motor Neuropathy",[3217],{"intervention":3241,"totalTrials":95,"cells":3242},"Aerobic exercise",{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3247,"PHASE3":3249,"PHASE4":3251,"NA":3253},{"trials":3244,"activeCount":99},[],{"trials":3246,"activeCount":99},[],{"trials":3248,"activeCount":99},[],{"trials":3250,"activeCount":99},[],{"trials":3252,"activeCount":99},[],{"trials":3254,"activeCount":99},[3255],{"nctId":3256,"briefTitle":3257,"status":244,"phases":3258,"primaryCompletion":3259,"completion":3259,"start":3260,"enrollment":3261,"conditions":3262,"interventions":3265},"NCT01893762","Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes",[92],"2013-12","2013-05",16,[3263,3264],"Upper Respiratory Tract Infections","URTI",[3241,3266],"Anaerobic exercise",{"intervention":3266,"totalTrials":95,"cells":3268},{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3270,"activeCount":99},[],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":99},[],{"trials":3278,"activeCount":99},[],{"trials":3280,"activeCount":99},[3281],{"nctId":3256,"briefTitle":3257,"status":244,"phases":3282,"primaryCompletion":3259,"completion":3259,"start":3260,"enrollment":3261,"conditions":3283,"interventions":3284},[92],[3263,3264],[3241,3266],{"intervention":3286,"totalTrials":95,"cells":3287},"Corticosteroid",{"EARLY_PHASE1":3288,"PHASE1":3290,"PHASE2":3292,"PHASE3":3294,"PHASE4":3296,"NA":3298},{"trials":3289,"activeCount":99},[],{"trials":3291,"activeCount":99},[],{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[3300],{"nctId":3301,"briefTitle":3302,"status":1254,"phases":3303,"primaryCompletion":3110,"completion":3304,"start":3305,"enrollment":3306,"conditions":3307,"interventions":3308},"NCT05606497","OPtimal TIming of COrticosteroids in Early-onset Fetal Growth REstriction: the OPTICORE Study",[],"2024-11-01","2022-05-11",1800,[2990],[3286],{"intervention":3310,"totalTrials":95,"cells":3311},"psyllium fibre",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[],{"trials":3317,"activeCount":99},[],{"trials":3319,"activeCount":99},[],{"trials":3321,"activeCount":99},[],{"trials":3323,"activeCount":99},[3324],{"nctId":3325,"briefTitle":3326,"status":244,"phases":3327,"completion":3137,"start":2060,"enrollment":3328,"conditions":3329,"interventions":3331},"NCT00189033","Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?",[92],285,[3330],"Colonic Diseases, Functional",[3310,3332,3333],"wheat bran","rice wheat",{"intervention":3332,"totalTrials":95,"cells":3335},{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3342,"PHASE4":3344,"NA":3346},{"trials":3337,"activeCount":99},[],{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[],{"trials":3343,"activeCount":99},[],{"trials":3345,"activeCount":99},[],{"trials":3347,"activeCount":99},[3348],{"nctId":3325,"briefTitle":3326,"status":244,"phases":3349,"completion":3137,"start":2060,"enrollment":3328,"conditions":3350,"interventions":3351},[92],[3330],[3310,3332,3333],{"intervention":3333,"totalTrials":95,"cells":3353},{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3355,"activeCount":99},[],{"trials":3357,"activeCount":99},[],{"trials":3359,"activeCount":99},[],{"trials":3361,"activeCount":99},[],{"trials":3363,"activeCount":99},[],{"trials":3365,"activeCount":99},[3366],{"nctId":3325,"briefTitle":3326,"status":244,"phases":3367,"completion":3137,"start":2060,"enrollment":3328,"conditions":3368,"interventions":3369},[92],[3330],[3310,3332,3333]]